Despite earlier detection and recent advances in surgery and radiation, prostate cancer is
second only to lung cancer in male cancer deaths in the United States. Hormone therapy in …

Androgen deprivation therapy (ADT) remains the primary treatment for advanced prostate
cancer. The efficacy of ADT has not been rigorously evaluated by demonstrating …

The importance of androgens and androgen receptors (AR) in primary prostate cancer is
well established. Metastatic disease is usually treated with some form of androgen ablation …

Prostate cancer (PC) remains a leading cause of cancer-related deaths among men
worldwide, despite continuously improved treatment strategies. Patients with metastatic …

Emergence of androgen-independent cancer cells during androgen deprivation therapy
presents a significant challenge to successful treatment outcomes in prostate cancer …

Androgen deprivation has been the standard therapy for advanced and metastatic prostate
cancer for over half a century, as prostate tumors are initially dependent on androgens for …

The androgen receptor (AR), ligand-induced transcription factor, is expressed in primary
prostate cancer and in metastases. AR regulates multiple cellular events, proliferation …

While androgen deprivation therapy (ADT) remains the primary treatment for metastatic
prostate cancer (PCa) since the seminal recognition of the disease as androgen-dependent …

Functional androgen receptor (AR) signaling is necessary for the development of prostate
cancer. The therapeutic effect of androgen deprivation therapy for prostate cancer was …

The prostate is an androgen-dependent organ that develops only in male mammals.
Prostate cancer is the most common nonskin malignancy in men and the second leading …